BIORESTORAT.THERAP.DL-01
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more
Market Cap & Net Worth: BIORESTORAT.THERAP.DL-01 (9OF)
BIORESTORAT.THERAP.DL-01 (F:9OF) has a market capitalization of $2.10 Million (€2.04 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #35217 globally and #4138 in its home market, demonstrating a 22.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIORESTORAT.THERAP.DL-01's stock price €0.23 by its total outstanding shares 8876242 (8.88 Million).
BIORESTORAT.THERAP.DL-01 Market Cap History: 2021 to 2026
BIORESTORAT.THERAP.DL-01's market capitalization history from 2021 to 2026. Data shows change from $31.89 Million to $2.10 Million (-53.09% CAGR).
BIORESTORAT.THERAP.DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIORESTORAT.THERAP.DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9OF by Market Capitalization
Companies near BIORESTORAT.THERAP.DL-01 in the global market cap rankings as of March 19, 2026.
Key companies related to BIORESTORAT.THERAP.DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BIORESTORAT.THERAP.DL-01 Historical Marketcap From 2021 to 2026
Between 2021 and today, BIORESTORAT.THERAP.DL-01's market cap moved from $31.89 Million to $ 2.10 Million, with a yearly change of -53.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.10 Million | -73.41% |
| 2025 | €7.88 Million | -36.86% |
| 2024 | €12.48 Million | -14.38% |
| 2023 | €14.58 Million | -34.43% |
| 2022 | €22.23 Million | -30.29% |
| 2021 | €31.89 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BIORESTORAT.THERAP.DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.10 Million USD |
| MoneyControl | $2.10 Million USD |
| MarketWatch | $2.10 Million USD |
| marketcap.company | $2.10 Million USD |
| Reuters | $2.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.